Browse RLTPR

Summary
SymbolRLTPR
NameRGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing
Aliases LRRC16C; CARMIL2; RGD, leucine-rich repeat, tropomodulin and proline-rich containing protein; leucine rich r ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 2: Cytoplasm Cytoplasm, cytoskeleton Cell membrane Peripheral membrane protein Cytoplasmic side Cell projection, lamellipodium Cell projection, ruffle Note=Colocalizes to dynamic vimentin filaments both in the central cytoplasm and at leading edges of migrating cells (PubMed:26578515, PubMed:26466680, PubMed:19846667). Colocalizes with F-actin, Arp2/3 complex and cortactin to leading edge lamellipodia, ruffles and macropinosomes of migrating cells (PubMed:26578515).
Domain PF16000 CARMIL C-terminus
PF13516 Leucine Rich repeat
Function

Cell membrane-cytoskeleton-associated protein that plays a role in the regulation of actin polymerization at the barbed end of actin filaments. Prevents F-actin heterodimeric capping protein (CP) activity at the leading edges of migrating cells, and hence generates uncapped barbed ends and enhances actin polymerization (PubMed:26466680). Plays a role in cell protrusion formations; involved in cell polarity, lamellipodial assembly, membrane ruffling and macropinosome formations (PubMed:19846667, PubMed:26578515, PubMed:26466680). Involved as well in cell migration and invadopodia formation during wound healing (PubMed:19846667, PubMed:26578515, PubMed:26466680).

> Gene Ontology
 
Biological Process GO:0002011 morphogenesis of an epithelial sheet
GO:0007015 actin filament organization
GO:0007163 establishment or maintenance of cell polarity
GO:0008064 regulation of actin polymerization or depolymerization
GO:0008154 actin polymerization or depolymerization
GO:0010591 regulation of lamellipodium assembly
GO:0010592 positive regulation of lamellipodium assembly
GO:0010639 negative regulation of organelle organization
GO:0010715 regulation of extracellular matrix disassembly
GO:0022617 extracellular matrix disassembly
GO:0030011 maintenance of cell polarity
GO:0030031 cell projection assembly
GO:0030032 lamellipodium assembly
GO:0030041 actin filament polymerization
GO:0030042 actin filament depolymerization
GO:0030198 extracellular matrix organization
GO:0030335 positive regulation of cell migration
GO:0030832 regulation of actin filament length
GO:0030833 regulation of actin filament polymerization
GO:0030834 regulation of actin filament depolymerization
GO:0030835 negative regulation of actin filament depolymerization
GO:0030836 positive regulation of actin filament depolymerization
GO:0030837 negative regulation of actin filament polymerization
GO:0030838 positive regulation of actin filament polymerization
GO:0031333 negative regulation of protein complex assembly
GO:0031334 positive regulation of protein complex assembly
GO:0031346 positive regulation of cell projection organization
GO:0031529 ruffle organization
GO:0032271 regulation of protein polymerization
GO:0032272 negative regulation of protein polymerization
GO:0032273 positive regulation of protein polymerization
GO:0032535 regulation of cellular component size
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0032984 macromolecular complex disassembly
GO:0040017 positive regulation of locomotion
GO:0043062 extracellular structure organization
GO:0043241 protein complex disassembly
GO:0043242 negative regulation of protein complex disassembly
GO:0043243 positive regulation of protein complex disassembly
GO:0043244 regulation of protein complex disassembly
GO:0043254 regulation of protein complex assembly
GO:0043624 cellular protein complex disassembly
GO:0044089 positive regulation of cellular component biogenesis
GO:0044319 wound healing, spreading of cells
GO:0051016 barbed-end actin filament capping
GO:0051258 protein polymerization
GO:0051261 protein depolymerization
GO:0051272 positive regulation of cellular component movement
GO:0051493 regulation of cytoskeleton organization
GO:0051494 negative regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0051639 actin filament network formation
GO:0051693 actin filament capping
GO:0060491 regulation of cell projection assembly
GO:0061339 establishment or maintenance of monopolar cell polarity
GO:0090066 regulation of anatomical structure size
GO:0090091 positive regulation of extracellular matrix disassembly
GO:0090504 epiboly
GO:0090505 epiboly involved in wound healing
GO:0097178 ruffle assembly
GO:0097581 lamellipodium organization
GO:1900027 regulation of ruffle assembly
GO:1900029 positive regulation of ruffle assembly
GO:1901879 regulation of protein depolymerization
GO:1901880 negative regulation of protein depolymerization
GO:1901881 positive regulation of protein depolymerization
GO:1902743 regulation of lamellipodium organization
GO:1902745 positive regulation of lamellipodium organization
GO:1903053 regulation of extracellular matrix organization
GO:1903055 positive regulation of extracellular matrix organization
GO:2000147 positive regulation of cell motility
GO:2000812 regulation of barbed-end actin filament capping
GO:2000813 negative regulation of barbed-end actin filament capping
Molecular Function GO:0005543 phospholipid binding
Cellular Component GO:0001726 ruffle
GO:0009898 cytoplasmic side of plasma membrane
GO:0015629 actin cytoskeleton
GO:0019897 extrinsic component of plasma membrane
GO:0019898 extrinsic component of membrane
GO:0030027 lamellipodium
GO:0031234 extrinsic component of cytoplasmic side of plasma membrane
GO:0031252 cell leading edge
GO:0044352 pinosome
GO:0044354 macropinosome
GO:0045111 intermediate filament cytoskeleton
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolRLTPR
NameRGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing
Aliases LRRC16C; CARMIL2; RGD, leucine-rich repeat, tropomodulin and proline-rich containing protein; leucine rich r ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RLTPR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between RLTPR and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28694326Primary Cutaneous T-Cell Non-Hodgkin LymphomaPromote immunityWe show that RLTPR (p.Q575E) increases binding of RLTPR to downstream components of the NF-κB signaling pathway, selectively upregulates the NF-κB pathway in activated T cells, and ultimately augments T-cell-receptor-dependent production of interleukin 2 by 34-fold.
Summary
SymbolRLTPR
NameRGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing
Aliases LRRC16C; CARMIL2; RGD, leucine-rich repeat, tropomodulin and proline-rich containing protein; leucine rich r ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RLTPR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRLTPR
NameRGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing
Aliases LRRC16C; CARMIL2; RGD, leucine-rich repeat, tropomodulin and proline-rich containing protein; leucine rich r ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RLTPR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.040.923
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3090.657
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.30.618
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4610.238
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8560.609
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0310.989
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.8030.108
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.2960.0926
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2410.774
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9280.231
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6260.546
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1310.525
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RLTPR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.16.84.30.443
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.18.52.60.702
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)862516.78.31
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolRLTPR
NameRGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing
Aliases LRRC16C; CARMIL2; RGD, leucine-rich repeat, tropomodulin and proline-rich containing protein; leucine rich r ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RLTPR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRLTPR
NameRGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing
Aliases LRRC16C; CARMIL2; RGD, leucine-rich repeat, tropomodulin and proline-rich containing protein; leucine rich r ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RLTPR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RLTPR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRLTPR
NameRGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing
Aliases LRRC16C; CARMIL2; RGD, leucine-rich repeat, tropomodulin and proline-rich containing protein; leucine rich r ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RLTPR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRLTPR
NameRGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing
Aliases LRRC16C; CARMIL2; RGD, leucine-rich repeat, tropomodulin and proline-rich containing protein; leucine rich r ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RLTPR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRLTPR
NameRGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing
Aliases LRRC16C; CARMIL2; RGD, leucine-rich repeat, tropomodulin and proline-rich containing protein; leucine rich r ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RLTPR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRLTPR
NameRGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing
Aliases LRRC16C; CARMIL2; RGD, leucine-rich repeat, tropomodulin and proline-rich containing protein; leucine rich r ......
Chromosomal Location16q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RLTPR collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.